Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM1032 in Advanced Solid Tumors
NCT05839106Phase 2Recruiting
- Sponsor
- Biotheus
- Start
- Jul 2022
- Primary completion
- Apr 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PM1032 in solid tumor, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 1 more, sponsored by Biotheus. Primary endpoints: Dose Limiting Toxicity at 21 days and Incidence and severity of treatment-related adverse events at 30 days. Started Jul 2022; status: recruiting.
02
Drugs
PM1032
03
Conditions
solid tumorgastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal cancer
Beyond the preview
Go deeper on NCT05839106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05839106.